Biological characterisation of HER2 amplified breast cancer

QR Code

Biological characterisation of HER2 amplified breast cancer

Breast carcinoma is the most frequent type of cancer affecting women. Among the recently described molecular and phenotypic classes of breast cancer, human epidermal growth factor receptor 2 (HER2)-positive tumours are associated with a poor prognosis. HER2 status is currently assessed in routine br...

Full description

Bibliographic Details
Main Author:	Barros, Fabrício Félix Tabuada
Format:	Thesis (University of Nottingham only)
Language:	English
Published:	2013
Online Access:	https://eprints.nottingham.ac.uk/13134/

Similar Items

Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
by: Drahman, Rosmaizan
Published: (2022)

Adjuvant trastuzumab in HER2-positive breast cancer.
by: Slamon, D., et al.
Published: (2011)

Expression of HER4 isoforms and HER4 localisation in HER2 negative breast cancer cell lines
by: Ali, Nursyazana Aqilah
Published: (2021)

Cytoplasmic and nuclear HER4 expression in HER2 negative breast cancer cell lines
by: Siti Norasikin Mohd Nafi,, et al.
Published: (2022)

The role of HER family signalling in breast cancer
by: Kuruppu, Anchala
Published: (2016)

Biological significance of human epidermal growth factor receptor 2 (HER2) in breast cancer: effect of oestrogen receptor
by: Ahmad, Dena Akram Jerjees
Published: (2016)

Computational pathology and deciphering the complexity of HER2 expression in breast cancer
by: Atallah, Nehal Mohammed
Published: (2025)

Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness
by: Chan, Arlene
Published: (2016)

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
by: Serra, V., et al.
Published: (2011)

Her2 challenge contest: a detailed assessment of automated her2 scoring algorithms in whole slide images of breast cancer tissues
by: Qaiser, Talha, et al.
Published: (2018)

Bioactivity of black cumin oil on the senescence of HER-2-overexpressing breast cancer cells
by: Faradiba Nur Ahlina,, et al.
Published: (2022)

Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply
by: Chan, Arlene, et al.
Published: (2016)

Translational control of Human Epidermal Growth Factor Receptors, HER2 and HER4 in response to cellular stresses in breast cancer cells
by: Edwards, Arnelle
Published: (2023)

Development of sandwich and label-free electrochemical immunosensor for detection of HER2 breast cancer biomarker
by: Lah, Zur Mira Azizah @ Nor Haiza
Published: (2018)

HER2 positive metastatic breast cancer: What happens after first line failure?
by: Chan, Arlene
Published: (2016)

The biological heterogeneity of oestrogen receptor positive breast cancer and its phenotypic characterisation
by: Habashy, Hany Onsy Fouad Ibrahim
Published: (2011)

BCL-2, HER1, HER2, HER3 and HER4 expression in primary colorectal adenocarcinoma
by: Ahmad Zubir, Nurul Mahirah
Published: (2017)

Expression of foxp3 tumour infiltrating lymphocytes in her2 positive breast cancer and their association with clinicopathological features
by: Hashim, Sobry
Published: (2023)

Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients
by: Aung, Sanda, et al.
Published: (2014)

Inhibition of HER2 enriches for Jagged1-dependent breast cancer stem cells: role for membrane Jagged1
by: Shah, Deep, et al.
Published: (2018)

Immunohistochemical detection of phospho-Akt, phospho-BAD, HER2 and oestrogen receptors α and β in Malaysian breast cancer patients
by: Seow, Heng Fong, et al.
Published: (2010)

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab
by: Chan, Arlene, et al.
Published: (2012)

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2014)

Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule
by: Nishimura, Yuya, et al.
Published: (2011)

Identification and characterisation of flotillin-2 as a molecular target in breast and bladder cancers
by: Jafarzadeh, Narges
Published: (2013)

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2013)

Gum Arabic and breast cancer biology: Biotechnology perspective
Published: (2025)

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2013)

Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.]
by: Hasbullah, Harissa H, et al.
Published: (2018)

Her beauty & her terror : portrait of an archetypal land
by: Frantom, Michelle
Published: (2014)

HER2/neu-based peptide vaccination-pulsed with B-cell epitope induced efficient prophylactic and therapeutic antitumor activities in TUBO breast cancer mice model
by: Nordin, Muhammad Luqman, et al.
Published: (2021)

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
by: Baselga, J., et al.
Published: (2017)

It's her platform
by: Lim, Teik Huat
Published: (2018)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan, Arlene, et al.
Published: (2012)

Association of Palb2 variants with risk to breast cancer and molecular characterisation of PALB2 tumours / Ng Pei Sze
by: Ng, Pei Sze
Published: (2021)

AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
by: Gianni, L., et al.
Published: (2013)

Development and Encapsulation of Affibody-Apoferritin Biologics for the Targeted Treatment of Breast Cancer
by: Holden, Isobel R
Published: (2025)

Her ideal platform
by: Lim, Teik Huat
Published: (2018)

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
by: Chan, Arlene, et al.
Published: (2016)

HerMES: Far infrared properties of known AGN in the HerMES fields
by: Hatziminaoglou, E., et al.
Published: (2010)